Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 1025.2 mg - injection, powder for - excipient ingredients: hydrochloric acid; sodium hydroxide - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.,vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - vancomycin hydrochloride, quantity: 512.6 mg - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - vancomycin baxter is indicated for potentially life threatening infections which cannot be treated with another effective, less toxic antimicrobial drug, including the penicillins and cephalosporins.,vancomycin baxter is useful in therapy of severe staphylococcal (including methicillin-resistant staphylococcal) infections in patients who cannot receive or who have failed to respond to the penicillins and cephalosporins or who have infections with staphylococci that are resistant to other antibiotics. once sensitivity data are available, therapy should be adjusted accordingly.,vancomycin baxter is effective alone or in combination with an aminoglycoside for endocarditis caused by s. viridans or s. bovis. for endocarditis caused by enterococci (e.g., s. faecalis), vancomycin is effective only in combination with an aminoglycoside. vancomycin is effective for the treatment of diphtheroid endocarditis. vancomycin baxter is used in combination with rifampicin, an aminoglycoside, or both in early onset prosthetic valve endocarditis caused by s. epidermidis or diphtheroids.,the effectiveness of vancomycin has been documented in other infections due to staphylococci including osteomyelitis, pneumonia, septicaemia and, skin and skin structure infections. when staphylococcal infections are localised and purulent, antibiotics are used as adjuncts to appropriate surgical measures.,specimens for bacteriological cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin.,vancomycin should be administered orally for the treatment of staphylococcal enterocolitis and antibiotic associated pseudomembranous colitis (produced by c. difficile). parenteral administration of vancomycin alone is inappropriate for this indication. vancomycin is not effective by the oral route for other types of infections. for oral administration the parenteral formulation may be used. some systemic absorption may occur following oral administration in patients with pseudomembranous colitis.

Európska únia - angličtina - EMA (European Medicines Agency)

valneva sweden ab - recombinant cholera toxin b subunit, vibrio cholerae 01 - cholera; immunization - vaccines - dukoral is indicated for active immunisation against disease caused by vibrio cholerae serogroup o1 in adults and children from 2 years of age who will be visiting endemic/epidemic areas.the use of dukoral should be determined on the basis of official recommendations taking into consideration the variability of epidemiology and the risk of contracting disease in different geographical areas and travelling conditions.dukoral should not replace standard protective measures. in the event of diarrhoea measures of rehydration should be instituted.

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

sp veterinaria, s.a. - doxycycline - oral powder - 500 milligram(s)/gram - doxycycline - bovine, fowl - chicken, fowl - turkey, porcine - antibiotics

Španielsko - angličtina - HMA (Heads of Medicines Agencies)

global vet health sl - enrofloxacin 100 mg - oral solution - chicken, turkeys - enrofloxacin

Maďarsko - angličtina - HMA (Heads of Medicines Agencies)

global vet health sl - enrofloxacin 100 mg - oral solution - chicken, turkeys - enrofloxacin

Portugalsko - angličtina - HMA (Heads of Medicines Agencies)

global vet health sl - enrofloxacin 100 mg - oral solution - chicken, turkeys - enrofloxacin

Rumunsko - angličtina - HMA (Heads of Medicines Agencies)

global vet health sl - enrofloxacin 100 mg - oral solution - chicken, turkeys - enrofloxacin

Nemecko - angličtina - HMA (Heads of Medicines Agencies)

dopharma research b. v. - phenylbutazone 200 mg/ml - oral powder - horses - phenylbutazone

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - aztreonam, quantity: 1 g - injection, powder for - excipient ingredients: arginine - indications as at 23 may 1991: 1. azactam is indicated for use as a single agent in the treatment of infections known or strongly suspected to be due to susceptible gram negative aerobes, such as urinary tract infection, gonorrhoea, etc. 2. in combination with other suitable antibiotics to treat serious infections due to problem organisms known or likely to be susceptible to aztreonam. some patients with serious pseudomonas infections may benefit from concurrent use of azactam and an aminoglycoside because of synergistic action. however, this enhanced activity is not predictable. if such concurrent therapy is considered in patients with serious infections, susceptibility tests should be performed in vitro to determine the activity of the drugs in combination. because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics, renal function should be monitored according to the aminoglycoside manufacturer's prescribing information, especially if high dosages of the aminoglycoside are to be u